New Verana Health AI Agent Boosts Efficiency and Compliance in MIPS Submissions
Agent Claire empowers clinicians to act faster, reduce risk, and improve operational performanceSAN FRANCISCO, April 28, 2026 /PRNewswire/ -- Verana...
Agent Claire empowers clinicians to act faster, reduce risk, and improve operational performanceSAN FRANCISCO, April 28, 2026 /PRNewswire/ -- Verana...
Agreement facilitates flexible, scalable automated industrialized production of rese-cel for many thousands of patients per year at a cost per...
CARSON CITY, Nev., April 27, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company...
Paul Hitchin to step down as of April 30, 2026Claire Hinshelwood appointed to CFO role as of May 1, 2026...
The virtual neurology clinic also offers comprehensive specialty care for epilepsy, chronic pain, concussion, memory conditions, and more; appointments are...
SOUTH SAN FRANCISCO, Calif., April 23, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, announced...
New 2026 report finds CEZIH has reached real national scale, with 15 million annual eReferrals, 61 million ePrescriptions, 300,000 daily...
New 2026 report finds CEZIH has reached real national scale, with 15 million annual eReferrals, 61 million ePrescriptions, 300,000 daily...
SAN DIEGO, April 22, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based...
Members of the Society of Interventional Radiology (SIR) and the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) Represent the...
- UNILATERAL MTLE: Low dose resulted in 89% median disabling seizure reduction in participants with MTS during the 7-12-month primary efficacy...
NEW YORK, April 22, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentation of data highlighting...
BPGbio Appoints Chas Bountra, Ph.D., as Executive Vice President and Chief Scientific Officer Chas Bountra, Ph.D., EVP and Chief Scientific...
ADAPT OCULUS is the first study to evaluate a targeted treatment for ocular MG, demonstrating that VYVGART significantly improves disease...
Oral presentation highlights additional data from PROGRESS Phase 2b study of pilavapadin supporting selection of 10mg as optimal dose for...
Three world-leading key opinion leaders, researchers and clinicians, join Clinical Advisory Board, reinforcing Bioxodes’ global registrational clinical strategy Positive ongoing discussions...
ESPOO, Finland, April 16, 2026 /PRNewswire/ -- New Finnish deep-tech company aims to make ultra-early disease detection possible through single-molecule...
The Cala kIQ Plus provides new therapy modes and adaptive calibration designed to optimize tremor relief and personalize treatment Data to...
Will play key role in strengthening cross-functional execution in support of global platform, scientific capabilities and partner delivery as well...
Findings underpin the scientific rationale for Anavex’s targeted autophagy approach with orally administered blarcamesine Convergence of impaired autophagy and synaptic...